Jeff Haxer
Partner,
Merger & Acquisition (M&A) expert in our Healthcare practice, including pharma, medical devices and insurance
Biografie Jeff
Expertise
- Expert in our M&A and Healthcare practices
- Leader of dozens of corporate and PE due diligence assessments, multiple post-merger integration assignments and several complex separations/carve-outs
- Co-author of Bain's POV on successful spin-offs as published in HBR
Jeff Haxer is the global leader of Bain's Divestitures and Spin-offs product. Previously, he led the M&A group within our Americas Healthcare and Life Sciences practice.
Jeff has led 40+ corporate and PE due diligence assessments, and advised on 25+ acquisition, divestiture, and spin-off transactions with a cumulative value of $200B+.
His industry experience includes pharmaceuticals (small and large molecule), medical devices, healthcare payer, healthcare provider, automotive, insurance, distribution (cold chain and non-cold chain), packaging (rigid and flexible), retail, restaurant and agriculture.
Jeff earned an MBA from the MIT Sloan School of Management and a BBA, with honors, from the University of Michigan.
Recent Insights
- “When a Spin-Off Wins Big,” Infografik, 2. Oktober 2023
- “Finding the Right Deals in Pharma M&A Now,” Infografik, 17. April 2023
- “Corporate M&A: Pressing “Pause”,” Global Healthcare Private Equity Report, 10. April 2023, Report
- “Healthcare and Life Sciences M&A,” M&A Report, 31. Januar 2023, Report
- “Few Corporate Spinoffs Deliver Value,” Harvard Business Review, 20. Dezember 2022, Artikel